It was actually back in 2005 that the first GLP-1 drug was approved to treat Type 2 diabetes, but unless you were directly affected, you probably didnt hear about these sorts of drugs until the more potent Ozempic entered our cultural lexicon
(Dali-Youcef and Andrs, 2009) Other people at risk include those who have had intestinal surgeries, or have chronic conditions which affect the gut , such as Crohns disease or celiac disease (Dahele and Ghosh, 2001)
Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity
For a supplier, the relevant argument is functional: an ingredient that allows one to achieve 30g of protein in a reduced format, without organoleptic compromise, meets a real formulation constraint, whether its linked to GLP-1 or not
These services can help with convenience, but physician oversight remains essential